Matrices listed below were spiked with certain level of Serpine1/PAI-1/PAI1/SERPINE1/Nexin/PLANH1/Endothelial plasminogen activator inhibitor/PAISerpin E1/PLANH1/plasminogen activator inhibitor 1/serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogenactivator inhibitor type 1) , member 1/serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitortype 1) , member 1 and the recovery rates were calculated by comparing the measured value to the expected amount of Serpine1/PAI-1/PAI1/SERPINE1/Nexin/PLANH1/Endothelial plasminogen activator inhibitor/PAISerpin E1/PLANH1/plasminogen activator inhibitor 1/serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogenactivator inhibitor type 1) , member 1/serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitortype 1) , member 1 in samples.
Matrix
Recovery range(%)
Average(%)
serum(n=5)
87-103
95
EDTA plasma(n=5)
88-96
92
heparin plasma(n=5)
85-104
93
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Serpine1/PAI-1/PAI1/SERPINE1/Nexin/PLANH1/Endothelial plasminogen activator inhibitor/PAISerpin E1/PLANH1/plasminogen activator inhibitor 1/serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogenactivator inhibitor type 1) , member 1/serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitortype 1) , member 1 and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.